We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Imperial College Acquires Gel Scanning System

By Biotechdaily staff writers
Posted on 28 Mar 2007
The Institute of Biomedical Engineering at Imperial College (London UK) has announced the acquisition of a Dyversity two-dimensional gel imaging system from Syngene (Cambridge, UK). More...


The Dyversity system, which has been fitted with precision made filters for its UV and visible lighting modules, will be used by up to 200 scientists a year in the Institute of Biomedical Engineering to record images of protein and DNA gels, as well as of blot assays stained with a range of visible, fluorescent, or chemiluminescent dyes. These activities will augment the multiplex imaging of 2-dimensional protein gels.

Syngene, a manufacturer of image analysis systems, is pleased to announce that one of the UK's universities, Imperial College London, has chosen Dyversity, its 2D gel imaging system, to assist in identifying the complex proteins associated with human diseases. The installation provides Syngene with another high-profile customer in the 2D gel market.

Dr Judith Nagy, a researcher at the Institute of Biomedical Engineering, explained, "When the Institute opened last year, we wanted to make sure that our core facilities would support all scientists in the institute and their multi-disciplinary research. This meant that we needed an image acquisition system that could be used in a wide range of research projects to perform the most demanding two-dimensional gel imaging, as well as the simplest gel documentation. Having evaluated four systems from major suppliers, we chose Dyversity because its functionality is equivalent to two imaging systems and a laser scanner, but in one unit. We are delighted to be the first site in the UK to have a Dyversity system.”

Laura Sullivan, divisional manager of Syngene said, "Imperial College is world-renowned for scientific excellence and cutting edge applied medical research. It is a great compliment to know such astute scientists have chosen a Dyversity system and that it will be used as part of so many important proteomics research programs.




Related Links:
Syngene
Imperial College

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.